311 related articles for article (PubMed ID: 16607372)
21. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass.
Montagnana M; Lippi G; Ruzzenente O; Bresciani V; Danese E; Scevarolli S; Salvagno GL; Giudici S; Franchi M; Guidi GC
J Clin Lab Anal; 2009; 23(5):331-5. PubMed ID: 19774626
[TBL] [Abstract][Full Text] [Related]
22. PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.
Galgano MT; Conaway M; Spencer AM; Paschal BM; Frierson HF
Hum Pathol; 2009 Oct; 40(10):1434-40. PubMed ID: 19427017
[TBL] [Abstract][Full Text] [Related]
23. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
[TBL] [Abstract][Full Text] [Related]
24. Effect of human epididymis protein 4 gene silencing on the malignant phenotype in ovarian cancer.
Zou SL; Chang XH; Ye X; Cheng HY; Cheng YX; Tang ZJ; Zhang ZJ; Gao L; Chen XH; Cui H
Chin Med J (Engl); 2011 Oct; 124(19):3133-40. PubMed ID: 22040568
[TBL] [Abstract][Full Text] [Related]
25. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
26. The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.
James NE; Emerson JB; Borgstadt AD; Beffa L; Oliver MT; Hovanesian V; Urh A; Singh RK; Rowswell-Turner R; DiSilvestro PA; Ou J; Moore RG; Ribeiro JR
Sci Rep; 2020 May; 10(1):8558. PubMed ID: 32444701
[TBL] [Abstract][Full Text] [Related]
27. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors.
Menz A; Weitbrecht T; Gorbokon N; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Bernreuther C; Lebok P; Clauditz T; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Burandt E; Krech R; Dum D; Krech T; Marx A; Simon R
Mol Med; 2021 Feb; 27(1):16. PubMed ID: 33588765
[TBL] [Abstract][Full Text] [Related]
29. Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site.
Celik B; Bulut T; Yalcin AD
Pathol Oncol Res; 2020 Apr; 26(2):1145-1151. PubMed ID: 31165997
[TBL] [Abstract][Full Text] [Related]
30. Application of mesothelin immunostaining in tumor diagnosis.
Ordóñez NG
Am J Surg Pathol; 2003 Nov; 27(11):1418-28. PubMed ID: 14576474
[TBL] [Abstract][Full Text] [Related]
31. Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer.
Chen Y; Chen Q; Liu Q; Gao F
Tumour Biol; 2016 Jun; 37(6):8359-65. PubMed ID: 26733162
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the gene expression profile in response to human epididymis protein 4 in epithelial ovarian cancer cells.
Zhu L; Guo Q; Jin S; Feng H; Zhuang H; Liu C; Tan M; Liu J; Li X; Lin B
Oncol Rep; 2016 Sep; 36(3):1592-604. PubMed ID: 27430660
[TBL] [Abstract][Full Text] [Related]
33. A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expression.
James NE; Gura M; Woodman M; Freiman RN; Ribeiro JR
Med Oncol; 2022 May; 39(5):71. PubMed ID: 35568777
[TBL] [Abstract][Full Text] [Related]
34. Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas.
O'Neal RL; Nam KT; LaFleur BJ; Barlow B; Nozaki K; Lee HJ; Kim WH; Yang HK; Shi C; Maitra A; Montgomery E; Washington MK; El Rifai W; Drapkin RI; Goldenring JR
Hum Pathol; 2013 May; 44(5):734-42. PubMed ID: 23084584
[TBL] [Abstract][Full Text] [Related]
35. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
36. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms.
Kubba LA; McCluggage WG; Liu J; Malpica A; Euscher ED; Silva EG; Deavers MT
Mod Pathol; 2008 Apr; 21(4):485-90. PubMed ID: 18246044
[TBL] [Abstract][Full Text] [Related]
37. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR; Baggerly K; Bast RC
Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter.
Berry NB; Cho YM; Harrington MA; Williams SD; Foley J; Nephew KP
Gynecol Oncol; 2004 Mar; 92(3):896-904. PubMed ID: 14984958
[TBL] [Abstract][Full Text] [Related]
39. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
[TBL] [Abstract][Full Text] [Related]
40. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
